Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4)
Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4)
复制标题
DOI：
10.1002/clc.22017
复制
发表时间：
2012-07-01
影响因子：
2.7
通讯作者：
Ambrosio, Giuseppe
中科院分区：
文献类型：
--
作者：
Borghi, Claudio;Ambrosioni, Ettore;Ambrosio, Giuseppe
背景资料：血管紧张素转换酶抑制剂（ACEIs）主要用于治疗左心室功能不全（LVD）患者，但与乙酰水杨酸（阿萨）合用可能会影响其疗效，不同化合物间存在一定差异。假设：由于两种ACEIs的药理学特性不同，阿萨与两种ACEIs佐芬普利和雷米普利之间的相互作用可能会对心脏病患者的生存产生不同的影响。研究方法：这项IIIb期、随机、双盲、平行组、多中心、欧洲研究在771例LVD（心力衰竭或左心室射血分数的临床体征）患者中比较了佐芬普利（60 mg/天）和雷米普利（10 mg/天）加阿萨（100 mg/天）的安全性和疗效
Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction